Navigation Links
Martek, General Mills Collaborate on Microencapsulation Technology for Food Applications

COLUMBIA, Md., Feb. 3 /PRNewswire/ -- DHA (docosahexaenoic acid) omega-3 innovator and maker of the life'sDHA(TM) brand of DHA, Martek Biosciences announced today that it has entered into a license agreement with General Mills for a patented microencapsulation technology. Microencapsulation is a process widely used in food manufacturing that protects the integrity of food ingredients and helps maintain the nutritional value, shelf-life and flavor of the finished food or beverage product.

Developed by General Mills, this technology is anticipated to enhance Martek's ability to produce high-quality, cost-effective DHA powders for certain food applications, particularly long-shelf life products and applications with sensory and formulation challenges. Under the terms of the agreement, Martek is granted a perpetual and generally exclusive license, with respect to third parties, to the General Mills technology for use with DHA and other polyunsaturated fatty acids. General Mills retains the right to this technology for its own use and exclusively for all uses within some of its core businesses.

"Through this technology, we look forward to providing the important health benefits of DHA to even more consumers around the world through healthy, convenient and high-quality products in a broad range of categories," said David Abramson, Martek president.

DHA omega-3 is a long-chain omega-3 fatty acid that serves as a primary building block for the brain and the eyes and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages benefit from an adequate supply of DHA omega-3 in their diets. Scientific reviews highlight the importance of DHA omega-3 in proper brain and eye development and function, as well as its importance in cardiovascular health. Clinical studies are underway to evaluate the role of DHA in decreasing the prevalence of certain neurological disorders. Leading experts around the world have noted that DHA is an important nutrient for health throughout the life cycle. Yet despite its importance, Americans have among the lowest dietary intakes of DHA omega-3 in the world.

Fish are often incorrectly thought to be the only source of DHA omega-3. However, life'sDHA offers a trusted, vegetarian form of DHA that contains no oceanic pollutants or toxins. Fish are sources of DHA because of the DHA-rich microalgae in their food chain; life'sDHA is derived directly from microalgae, a renewable, sustainable source of DHA that does not deplete ocean resources, and is produced entirely in the U.S. in an FDA-inspected facility. Today, life'sDHA is found in numerous foods, beverages and supplements for people of all ages. It is also the only source of DHA used in U.S. infant formula and is included in more than 99 percent of all formulas on the U.S. market, as well as in more than 200 brands of infant formula, nutritional supplements and functional foods sold in over 75 countries worldwide.

One of the world's leading food companies, General Mills operates in over 100 countries and markets more than 100 consumer brands, including Cheerios, Haagen-Dazs, Nature Valley, Betty Crocker, Pillsbury, Green Giant, Old El Paso, Progresso, Cascadian Farms, Muir Glen and more. Headquartered in Minneapolis, Minnesota, U.S.A., General Mills had fiscal 2008 global net sales of U.S. $14.9 billion, including the company's $1.2 billion proportionate share of joint venture net sales. Visit

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA, a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit For a complete list of products containing life'sDHA, visit .

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

              Cassie France-Kelly
              Public Relations, Martek
              (443) 542-2116

              Kyle Stults
              Investor Relations, Martek
              (410) 740-0081

SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lafayette General Medical Center is the First Hospital in Louisiana to Use Genetic-Based Technology to Test for Respiratory Disease
2. Senetek PLC Announces 2008 Annual General Meeting Voting Results
3. Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response
4. PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery
5. Environmental Tectonics Corporations BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital
6. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
7. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
8. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
9. Results of the Annual General Meeting Held on September 24, 2008
10. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
11. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... additional independent director, and the Company welcomes Neil ... in a recent anonymous internet report on NW Bio.  ... Linda Powers stated, "We agree with ...
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... announced today that it has closed the sale of ... to Guerbet (GBT- NYSE Euronext) in a transaction valued ... four manufacturing facilities and a total of approximately 1,000 ... the St. Louis area. This ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
Breaking Biology News(10 mins):